Hormones

Enclomiphene

Evidence: moderate_human

Mechanism of Action

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Dosing Protocol

Standard: Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Maintenance: Research indicates 12.5-25 mg daily, with dose titrated based on serum testosterone and gonadotropin levels.

Administration: oral

Timing: Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Duration: Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Notes

Enclomiphene is increasingly preferred over racemic clomiphene for long-term SERM-based testosterone restoration because it avoids zuclomiphene accumulation (the estrogenic isomer). Phase 2 trials demonstrated testosterone elevation to the 400-600 ng/dL range with preserved sperm counts. Required bloodwork: Total testosterone, free testosterone, LH, FSH, estradiol, SHBG at baseline and every 4-8 weeks during titration. Liver function panel at baseline and every 3 months. Once stable, monitoring every 3-6 months. This is a rapidly evolving area — monitor for FDA approval updates. Medical supervision required.

Stacking

  • Anastrozole (low-dose, if E2 rises excessively)
  • hCG (transitional — used prior to switching to enclomiphene)
  • Zinc and Boron (micronutrient support for testosterone synthesis)

Interactions

  • Exogenous testosterone [HIGH] — Directly antagonistic mechanisms — exogenous T suppresses the HPG axis that enclomiphene stimulates.
  • Aromatase inhibitors [MEDIUM] — Excessive estrogen suppression may reduce the substrate for enclomiphene's mechanism. Low-dose AI only if symptomatic.
  • Clomiphene (racemic) [LOW] — Do not combine — enclomiphene replaces racemic clomiphene with a cleaner pharmacological profile.
  • May alter estradiol dynamics and fertility strategies

Contraindications

  • Primary hypogonadism (elevated gonadotropins, testicular failure)
  • Severe hepatic impairment
  • Known hypersensitivity to clomiphene isomers
  • Pituitary tumors
  • Vision changes or thrombotic history warrant caution

Side Effects

  • Headache
  • Hot flashes
  • Nausea (less common than racemic clomiphene)
  • Elevated estradiol (from increased testosterone substrate for aromatase)
  • Rare visual disturbances (significantly less than racemic clomiphene)

Key Papers

  • 10.1016/j.fertnstert.2014.06.004
  • 10.1111/cen.12502
  • 10.1016/j.jsxm.2015.06.017
  • Male endocrine studies on enclomiphene citrate

Source Quality

Not yet FDA-approved (as of 2025, Androxal has not received FDA approval). Available through compounding pharmacies and research chemical suppliers. Pharmaceutical-grade enclomiphene citrate from compounding pharmacies preferred.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should Enclomiphene Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds